英国高危人群与老年人接种COVID-19疫苗的成本效果:动态传播模型预测
本研究使用SEIR模型和决策树,评估英国秋季针对≥65岁及6月龄-64岁高危人群接种变异适配mRNA-1273疫苗的临床影响与成本效果。结果显示,与不接种相比,该策略减少症状感染、住院、死亡和长新冠,并节省成本、增加QALY,ICER为£8963/QALY;缩小接种资格至≥75岁及6月龄-74岁高危人群则预防效果更少,且广泛接种相比窄人群接种的ICER为£11,753/QALY。结论认为当前策略仍具成本效果。
要点
- 秋季接种mRNA-1273可减少症状感染、住院、死亡和长新冠。
- 与不接种相比,ICER为£8963/QALY,节省£467.7百万。
- 缩小接种资格至≥75岁及6月龄-74岁高危者预防效果更少。
核心结论
- 对≥65岁成人及6月龄-64岁高危人群接种COVID-19疫苗,与不接种和窄人群接种相比均具成本效果。
研究设计与样本
- 使用SEIR模型预测英国COVID-19病例和住院,结合决策树预测健康结果、成本和QALY损失,时间跨度1年。
- 目标人群为≥65岁成人及6月龄-64岁重症高危人群(基础病例人群)。
主要发现
- COVID-19相关死亡减少7200例,长新冠减少18000例。
- 节省成本£467.7百万,获得52000个QALY,ICER为£8963/QALY。
- 缩小接种资格至≥75岁及6月龄-74岁高危人群,相比基础病例人群,症状感染增加525300例,住院增加6000例,死亡增加1100例,长新冠增加5200例。
- 广泛人群接种相比窄人群接种的ICER为£11,753/QALY。
关键数值与推荐
- 基础病例人群:≥65岁成人及6月龄-64岁重症高危人群。
- 窄人群:≥75岁成人及6月龄-74岁重症高危人群。
- ICER阈值未在原文中报告。
临床怎么用
- 维持对≥65岁成人及6月龄-64岁高危人群的秋季COVID-19疫苗接种策略具有成本效果。
- 缩小接种资格至≥75岁及6月龄-74岁高危人群将导致更多感染、住院、死亡和长新冠,且成本效果仍可接受但预防效果更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study estimates the potential clinical impact and cost-effectiveness of an Autumn COVID-19 vaccination campaign in the United Kingdom (UK) using a variant-adapted mRNA-1273 vaccine in those aged ≥65 years and those aged 6 months-64 years at high risk (base case population) of severe outcomes, as well as the effect of implementing more restrictive vaccine eligibility requirements. METHODS: A Susceptible-Exposed-Infected-Recovered (SEIR) model was used to predict COVID-19 cases and hospitalisations in the UK. A COVID-19 vaccination and infection consequences decision tree was used to predict health outcomes, costs and quality-adjusted life-year (QALY) losses associated with symptomatic SARS-CoV-2 infections as well as costs and QALY losses associated with COVID-19 vaccination and adverse events over a 1-year time horizon. RESULTS: Compared to no vaccination, an Autumn mRNA-1273 vaccination campaign is predicted to decrease the number of symptomatic infections from 21.9 million to 20.0 million, and the number of hospitalisations from 150,000 to 116,000. COVID-related deaths and long COVID cases are decreased by 7200 and 18,000, respectively. Costs saved are £467.7 million with 52,000 QALYs gained, resulting in an incremental cost-effectiveness ratio (ICER) of £8963/QALY gained. The ICER was most sensitive to infection incidence, population immunity before the vaccination campaign, vaccine effectiveness against hospitalisation, and hospitalisation probabilities. Narrowing the vaccination eligibility criteria to those aged ≥75 years and those aged 6 months-74 years at high risk of severe outcomes results in fewer outcomes prevented, with 525,300 more symptomatic infections, 6000 more hospitalisations, 1100 additional deaths, and 5200 additional cases of long COVID, compared to the base case. Vaccination of the broader population compared to the narrower population is associated with an ICER of £11,753/QALY gained. CONCLUSIONS: Vaccinating adults aged ≥65 years and high-risk individuals 6 months-64 years remains cost-effective compared both to no vaccination and vaccination of the narrower population.
引用
- Kohli M, Maschio M, Lee A, et al. The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model. Vaccine. 2026. PMID: 42140088. doi:10.1016/j.vaccine.2026.128687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。